ライフサイエンスコーパス: hypertensive patient

1 a high index of suspicion is needed in every hypertensive patient.

2 of uncomplicated hypertension in the elderly hypertensive patient.

3 that impaired corin activation activity in a hypertensive patient.

4 ary care providers and their black and white hypertensive patients.

5 r combination on the reduction of LV mass in hypertensive patients.

6 oves peripheral insulin sensitivity in obese hypertensive patients.

7 risk of cardiovascular events and death for hypertensive patients.

8 ion, and genetic variations of RGS2 occur in hypertensive patients.

9 n and stroke among pharmacologically treated hypertensive patients.

10 ated rise in exercise blood pressure (BP) in hypertensive patients.

11 value in predicting cardiovascular events in hypertensive patients.

12 ve heart failure, similar to untreated human hypertensive patients.

13 of cardiovascular morbidity and mortality in hypertensive patients.

14 of bone morphogenetic protein receptor-2 in hypertensive patients.

15 wering strategies in older (age >/=65 years) hypertensive patients.

16 of ECG LVH may predict improved prognosis in hypertensive patients.

17 that ADAM17 was upregulated in the brain of hypertensive patients.

18 ndothelium-dependent vasodilator function of hypertensive patients.

19 echanism for promotion of atherosclerosis in hypertensive patients.

20 on and tested its potential to risk-stratify hypertensive patients.

21 ar properties and outcomes of lean and obese hypertensive patients.

22 hrine (200% vs. 500%, p < 0.05) in the obese hypertensive patients.

23 NE) (p < 0.01) in the lean but not the obese hypertensive patients.

24 and lean (BMI = 24.3 +/- 0.2 kg/m2, n = 66) hypertensive patients.

25 the selection of drugs for the treatment of hypertensive patients.

26 he pathogenesis of cardiovascular disease in hypertensive patients.

27 ion with a prevalence of 5-10% in unreferred hypertensive patients.

28 lar cAMP, in 12 normotensive subjects and 12 hypertensive patients.

29 nts similar to those seen in untreated human hypertensive patients.

30 uretics would reduce the number of resistant hypertensive patients.

31 ity, and non-cardiovascular complications in hypertensive patients.

32 ciated increased atherosclerosis observed in hypertensive patients.

33 ventricular (LV) mass and wall thickness in hypertensive patients.

34 ay increase coronary heart disease events in hypertensive patients.

35 -sodium diets are frequently recommended for hypertensive patients.

36 nvasive central BP monitoring in elderly and hypertensive patients.

37 c and renal artery repair in 133 consecutive hypertensive patients.

38 ) were a stratified random sample of treated hypertensive patients.

39 l be effective in reducing blood pressure in hypertensive patients.

40 tandard natural virgin olive oil in pre- and hypertensive patients.

41 ypertension treatment is beneficial for most hypertensive patients.

42 e effects of FVOO on endothelial function in hypertensive patients.

43 cardiovascular disease outcomes or death in hypertensive patients.

44 predict the onset of vascular dysfunction in hypertensive patients.

45 ng BT into beneficial dietary supplements in hypertensive patients.

46 (mass/end-diastolic volume [M/EDV](2/3)) in hypertensive patients.

47 s can decrease time to BP target among their hypertensive patients.

48 duction in the time to BP target among their hypertensive patients.

49 c sympathetic baroreflex function in elderly hypertensive patients.

50 mation for the clinical management of ocular hypertensive patients.

51 oversial in the treatment of acute stroke in hypertensive patients.

52 asures in diagnosing and adequately treating hypertensive patients.

53 e and aldosterone phenotype in a subgroup of hypertensive patients.

54 r patients with hypertension compared to non-hypertensive patients.

55 l benefits of renal denervation in resistant hypertensive patients.

56 A total of 9193 hypertensive patients (1195 with diabetes) in the Losart

57 Among hypertensive patients, 22% with LVH had an abnormally lo

58 Endothelin was higher in hypertensive patients (4.6+/-0.2 fmol/mL) than in 20 con

59 t reliability of LV mass measurements in 183 hypertensive patients (68% men, 65 +/- 9 years) enrolled

60 and fractionated catecholamines, and, in the hypertensive patient, a serum potassium level and plasma

61 In hypertensive patients, a combined ET(A/B) blockade resul

62 smography in 37 normotensive patients and 27 hypertensive patients according to race.

63 ndomized, clinical trial in 33,357 high-risk hypertensive patients aged > or =55 years.

64 uretic-based regimens versus placebo in 4396 hypertensive patients aged 65-74 years.

65 Of 19342 hypertensive patients (aged 40-79 years with at least th

66 ess than 140/less than 90 mmHg in 50% of all hypertensive patients, an increase from 27% in 1988-1994

67 ress were compared in 12 normal subjects, 12 hypertensive patients and 10 hypercholesterolemic patien

68 y of the RI was examined in 256 asymptomatic hypertensive patients and 10 patients with heart failure

69 A cohort of 582 881 hypertensive patients and 260 924 normotensive individua

70 METHODS AND Cohort study included 92 hypertensive patients and 27 providers in 3 safety-net p

71 ceptors in pulmonary arteries from pulmonary hypertensive patients and control subjects, using in vit

72 nce of this ADAM17-mediated ACE2 shedding in hypertensive patients and further identify the cell type

73 +)/H(+) exchanger, has increased activity in hypertensive patients and in animal models of hypertensi

74 enzyme (ACE) inhibitors and beta-blockers in hypertensive patients and in patients with heart failure

75 independent predictor of clinical events in hypertensive patients and in the general population.

76 that RI provides an approach for stratifying hypertensive patients and is suitable for testing in oth

77 (-)-epicatechin reduces blood pressure in hypertensive patients and limits infarct size in animal

78 cies of the two variants were similar in the hypertensive patients and the control subjects.

79 dies of patients with early glaucoma, ocular hypertensive patients, and age-matched control subjects,

80 en 1966 and end 2013 in cohorts with >/= 40% hypertensive patients, and exclusive of trials in acute

81 on was more frequent in older patients, men, hypertensive patients, and those presenting with ST-segm

82 frican American patients, Hispanic patients, hypertensive patients, and those with hypertrophy.

83 have increased risk compared with unselected hypertensive patients, and use of hospitalization for he

84 ingle nucleotide polymorphisms identified in hypertensive patients are located in the human RGS2 prom

85 patients, cardiovascular properties in lean hypertensive patients are more dependent on catecholamin

86 Hypertensive patients are often given a calcium antagoni

87 bleeds which predicts cerebral hemorrhage in hypertensive patients, as well as progression to hyperte

88 bidity and mortality more than amlodipine in hypertensive patients at high cardiovascular risk.

89 portance of prompt blood-pressure control in hypertensive patients at high cardiovascular risk.

90 ge randomized trials that randomly allocated hypertensive patients at high risk for cardiovascular di

91 Increased pulse pressure may help identify hypertensive patients at high risk for overt CHF who are

92 ECG strain identifies hypertensive patients at increased risk of developing CH

93 Development of new-onset AF identifies hypertensive patients at increased risk of SCD.

94 t of proteinuria was highest in persistently hypertensive patients between years 1-3.

95 Among hypertensive patients, black patients were 2.5 to 2.9 an

96 In a fourth study, 6 hypertensive patients (blood pressure >160/100 mm Hg) re

97 th, but at 6 months, levels were elevated in hypertensive patients but not in normotensive patients (

98 sion significantly lowered blood pressure in hypertensive patients but not in normotensive subjects (

99 dysfunction is reported to occur in treated hypertensive patients but not seen normotensive subjects

100 s contribute to vascular remodeling in obese hypertensive patients by activating protein kinase C (PK

101 Compared with obese hypertensive patients, cardiovascular properties in lean

102 In mildly to moderately hypertensive patients, carotid intima-media thickness an

103 and applanation tonometry in 271 unmedicated hypertensive patients classified by echocardiography as

104 Among examined cognitive variables, hypertensive patients committed significantly more perse

105 response to ACh was significantly blunted in hypertensive patients compared with controls (P<0.001),

106 in both mRNA and protein FGF1 expression in hypertensive patients compared with normotensive control

107 ased after transplant and was greater in the hypertensive patients compared with the normotensive pat

108 declined by 8%; use of antihypertensives by hypertensive patients decreased by 10%.

109 compared with less than 140 mmHg in diabetic hypertensive patients does not appear to decrease the de

110 reactive pulmonary vasculature in pulmonary hypertensive patients during acute vasodilator testing a

111 morbidity and mortality have been reduced in hypertensive patients, even in those with hyperlipidemia

112 Compared with controls, hypertensive patients exhibited a decreased flow-mediate

113 140 image pairs from 100 glaucomatous/ocular hypertensive patient eyes using a handheld stereo viewer

114 In hypertensive patients, fenoldopam rapidly decreases bloo

115 ar dysfunction in approximately one fifth of hypertensive patients for whom concomitant LVH was found

116 We selected 1447 hypertensive patients from a 3-year benazepril postmarke

117 ficantly reduced after vitamin C infusion in hypertensive patients (from 53.3 +/- 12.2 to 47.4 +/- 11

118 Hypertensive patients had elevated CHGA coupled with red

119 an normotensive subjects, the lean and obese hypertensive patients had greater left ventricular mass

120 Female, elderly, diabetic and hypertensive patients had longer delays at all stages.

121 Lowering of blood pressure in hypertensive patients has been reported to reduce morbid

122 Hypertensive patients have been found to be associated w

123 ual variability in blood pressure in treated hypertensive patients have been ignored.

124 Hypertensive patients have both impaired endothelium-dep

125 Moreover, human hypertensive patients have demonstrated increased suscep

126 An appreciable proportion of asymptomatic hypertensive patients have depressed left ventricular (L

127 Although lean hypertensive patients have fewer metabolic abnormalities

128 Hypertensive patients have impaired endothelium-dependen

129 Approximately 5% of all hypertensive patients have renovascular hypertension, al

130 In 9 normal controls (NC), 11 hypertensive patients (HT), and 12 hypercholesterolemic

131 ug) as initial therapy in several subsets of hypertensive patients (i.e., those with diabetes and nep

132 content, we analyzed samples from 14 mildly hypertensive patients in a crossover study during a high

133 ntly reduce cardiovascular events in treated hypertensive patients in ASCOT did not influence central

134 ss (22%) in the obese than in the lean (55%) hypertensive patients in response to standing (p < 0.05)

135 baseline and after 1 year of therapy in 7409 hypertensive patients in the LIFE study (Losartan Interv

136 ly important in treated mildly to moderately hypertensive patients in whom treatment aims at avoiding

137 ulse pressure ratio) was reduced in the lean hypertensive patients, in whom it correlated (p = 0.033)

138 dent predictor of cardiovascular outcomes in hypertensive patients including myocardial infarction, f

139 e plays a role in endothelial dysfunction in hypertensive patients independent of insulin resistance.

140 rosis and to increased arterial stiffness in hypertensive patients, independent of age.

141 ith the risk of primary cardiac arrest among hypertensive patients, independent of conventional binar

142 In older hypertensive patients, intensive BP control (systolic BP

143 ertaken conservatively since the chronically hypertensive patient is at risk for ischemic brain injur

144 igate whether the endothelial dysfunction of hypertensive patients is related to a selective defect i

145 ing self-monitoring to no self-monitoring in hypertensive patients (June 2016).

146 DAM17-mediated ACE2 shedding in the brain of hypertensive patients, leading to a loss in compensatory

147 f late gadolinium enhancement, as well as of hypertensive patients LV wall thickness of >15 mm (P<0.0

148 erm safety, these data suggest that selected hypertensive patients may be accepted for living kidney

149 oleic acid concentrations observed in obese hypertensive patients may contribute to vascular remodel

150 Heart failure (HF) developing in hypertensive patients may occur with preserved or reduce

151 In addition, within hypertensive patients (n = 469), patients using angioten

152 Interestingly, untreated hypertensive patients (n=20) had a cerebral blood flow s

153 Finally, using ELISA, we found that hypertensive patients (n=31) have higher plasma levels o

154 Most hypertensive patients need two or more drugs for blood-p

155 d whether diastolic function differs between hypertensive patients of African-Caribbean or white Euro

156 Diastolic function is significantly worse in hypertensive patients of African-Caribbean origin than i

157 clude variation in the mechanisms at work in hypertensive patients of different races and variation i

158 We randomized 126 hypertensive patients on hemodialysis to a standardized

159 Treatment of hypertensive patients over age 80 with indapamide and an

160 significant increase in FBF from baseline in hypertensive patients (P<0.008) but not in controls (P=0

161 +/-1.4 s(-1) (95% CI, -0.8 to -2.6 s(-1)) in hypertensive patients (P=0.0003).

162 mic patients (p=0.03 vs. saline), but not in hypertensive patients (p=0.69 vs. saline).

163 In previous clinical trials in high-risk hypertensive patients, paradoxically higher cardiovascul

164 ave fewer metabolic abnormalities than obese hypertensive patients, paradoxically they appear to have

165 y be considered for primary AF prevention in hypertensive patients, previous studies have yielded con

166 In hypertensive patients, primary prevention of HF is stron

167 and sex-matched RA-normotensive (n = 13), RA-hypertensive patients (RA-HTN; n = 17), normotensive (NC

168 Thirteen pre- and stage-1 hypertensive patients received a single dose of 30 mL of

169 We aimed to assess the risk of cancer in hypertensive patients receiving ACE inhibitors or other

170 turnal arterial hypotension, particularly in hypertensive patients receiving oral hypertensive therap

171 Treating hypercholesterolemia in hypertensive patients reduces residual CHD risk >35%.

172 and resistance arteries in normotensive and hypertensive patients referred for cardiac catheterizati

173 sm but instead can be effective in resistant hypertensive patients regardless of aldosterone levels.

174 Na(+)-Li+ exchange are elevated in essential hypertensive patients relative to normotensive individua

175 bled the risk for heart failure in high-risk hypertensive patients (relative risk, 2.04 [95% CI, 1.79

176 Despite progress, many hypertensive patients remain uncontrolled.

177 There is a marked variability in hypertensive patients' response to different antihyperte

178 icacy of antihypertensive agents in treating hypertensive patients, safety and efficacy of antihypert

179 A total of 346 uncontrolled hypertensive patients, separated according to daytime am

180 eased use of healthcare resources, resistant hypertensive patients should be identified early, and gr

181 On the contrary, in 16 hypertensive patients, sodium nitroprusside in equidepre

182 ertension is a valuable approach to managing hypertensive patients suffering from acute ischemic stro

183 characterized cohort of untreated borderline hypertensive patients suggested that ARHGAP42 genotype h

184 was twofold greater (p < 0.05) in pulmonary hypertensive patients than in control subjects.

185 h urinary nitrate excretion was lower in the hypertensive patients than in the control group (mean 45

186 interventions provides multiple benefits to hypertensive patients that extend beyond a reduction in

187 Only a single study has been reported in hypertensive patients that links baseline sodium, measur

188 me (ACE) inhibitors reduce blood pressure in hypertensive patients, the clinical trial evidence in te

189 In high-cardiovascular-risk treated hypertensive patients, the incidence of cardiovascular e

190 In contrast, in hypertensive patients, the vasodilator effect of ET(A) r

191 ndothelium-dependent vasodilator function in hypertensive patients, thereby suggesting that an increa

192 To evaluate the heightened risks in lean hypertensive patients, this study compared metabolic, ne

193 s issue further, we studied a large group of hypertensive patients to investigate the relation of cal

194 might explain an increased susceptibility of hypertensive patients to vascular damage over repeated e

195 f antihypertensive drugs, in untreated young hypertensive patients, to assess the response rate with

196 that found increased risk of sudden death in hypertensive patients treated with non-potassium-sparing

197 Hypertensive patients underwent multimodal cardiac asses

198 were measured in 2937 mildly and moderately hypertensive patients unmedicated for > or = 3-4 wk.

199 y of retinopathy was significantly higher in hypertensive patients versus those without hypertension

200 out hypertension, upregulation of chymase in hypertensive patients was much stronger than that seen i

201 Nerve anatomy in hypertensive patients was not considerably different com

202 However, HHcy's role in hypertensive patients was not studied.

203 n, which routinely hampers the management of hypertensive patients, was absent in knock-ins.

204 In hypertensive patients, we found that arteriosclerosis wa

205 Four of fourteen hypertensive patients were able to discontinue antihyper

206 rential end-systolic stress relations in 294 hypertensive patients were analyzed as predictors of the

207 Hypertensive patients were compared with nonhypertensive

208 eart Attack Trial (ALLHAT), 42 418 high-risk hypertensive patients were randomized to chlorthalidone,

209 ELT can be considered in glaucoma and ocular hypertensive patients whenever cataract surgery is perfo

210 to reduce cardiovascular adrenergic drive in hypertensive patients, which suggests that oxidative str

211 ACE2 activity in the cerebrospinal fluid of hypertensive patients, which was correlated with systoli

212 Hypertensive patients who are healthy, functionally inde

213 revention of coronary heart disease (CHD) in hypertensive patients who are not conventionally deemed

214 pared with patients who did not develop CHF, hypertensive patients who developed CHF were older; were

215 We used a retrospective cohort study of hypertensive patients who had filled prescriptions for 1

216 Cases (n = 189) were hypertensive patients who had had a first cardiovascular

217 Cases (n = 131) were treated hypertensive patients who had had a primary cardiac arre

218 abnormalities were identified in white-coat hypertensive patients who had no identifiable structural

219 may decrease retinopathy progression in non-hypertensive patients who have type 1 diabetes with litt

220 use of amiloride plus hydrochlorothiazide in hypertensive patients who need treatment with a diuretic

221 We enrolled 16 hypertensive patients who responded to treatment with an

222 d random sample of pharmacologically treated hypertensive patients who were matched to MI cases by ag

223 n of Ang II (3 ng x kg(-1) x min(-1)) in 190 hypertensive patients who were on carefully controlled h

224 In one (1.1%) hypertensive patient, who developed bilateral branch ret

225 ith PegIFNalpha and ribavirin, especially in hypertensive patients, who may develop serious complicat

226 e main outcome measure was the percentage of hypertensive patients whose hypertension was controlled

227 hould be considered in the evaluation of the hypertensive patient with poor blood pressure control.

228 In hypertensive patients with a low plasma renin but normal

229 Twelve hypertensive patients with a mean ambulatory blood press

230 4 high-quality trials involving 10,857 older hypertensive patients with a mean follow-up of 3.1 years

231 ischemic events may occur more frequently in hypertensive patients with activated renin-angiotensin s

232 mage and accelerated kidney function loss in hypertensive patients with and without chronic kidney di

233 nance imaging to accurately quantify LVM, in hypertensive patients with and without LVH and in normal

234 In hypertensive patients with aorto-ostial atherosclerotic

235 s of renal artery stent revascularization in hypertensive patients with aorto-ostial atherosclerotic

236 in asymptomatic high-risk prehypertensive or hypertensive patients with blood pressure (BP) controlle

237 Factors leading to adverse outcomes in hypertensive patients with CAD are poorly understood.

238 dolapril STudy (INVEST) compared outcomes in hypertensive patients with CAD that were assigned random

239 In hypertensive patients with CAD who are >/=60 years of ag

240 In hypertensive patients with CAD, increased risk for adver

241 This is a post hoc analysis of hypertensive patients with CAD.

242 Twenty hypertensive patients with CFDI suggestive of RA FMD (mi

243 determine predictors for adverse outcomes in hypertensive patients with coronary artery disease (CAD)

244 rdial infarction [MI] or nonfatal stroke) in hypertensive patients with coronary artery disease (CAD)

245 Hypertensive patients with diabetes have less regression

246 cohort study, we analyzed treatment of 8127 hypertensive patients with diabetes mellitus treated by

247 ain the higher CV morbidity and mortality in hypertensive patients with diabetes, and the absence of

248 useful as a surrogate marker of outcomes in hypertensive patients with diabetes.

249 cular disease and to 44 age- and sex-matched hypertensive patients with diastolic dysfunction (hypert

250 glaucoma was six times more likely in ocular hypertensive patients with disc hemorrhages compared wit

251 grams were examined at study baseline in 886 hypertensive patients with ECG LVH by Cornell voltage-du

252 versus atenolol therapy was assessed in 9193 hypertensive patients with ECG LVH by Sokolow-Lyon volta

253 of SCD to new-onset AF was evaluated in 8831 hypertensive patients with electrocardiographic left ven

254 In these treated male hypertensive patients with good blood pressure control (

255 perties and therefore has a role in treating hypertensive patients with gout.

256 ive myocardial CCL is associated with HHF in hypertensive patients with HF.

257 rebral vessels were most frequently found in hypertensive patients with high and very high total card

258 Hypertensive patients with hyperaldosteronism or normal

259 Hypertensive patients with hypokalaemia, together with t

260 tan-based to atenolol-based therapy in 9,193 hypertensive patients with left ventricular hypertrophy

261 between the ADC value and systolic strain in hypertensive patients with left ventricular hypertrophy

262 is measure of myocardial end-organ damage in hypertensive patients with LV hypertrophy.

263 By contrast, hypertensive patients with LVH (group 2), had significan

264 ventricular hypertrophy (LVH) (n = 80), and hypertensive patients with LVH on resting electrocardiog

265 Finally, in 39 hypertensive patients with LVH, conduit and resistance a

266 divided into three groups: group 1: n = 13, hypertensive patients with LVH; group 2: n = 30, hyperte

267 uction (LIFE) echocardiography substudy, 939 hypertensive patients with measurable LVM at baseline we

268 We randomly assigned 1715 hypertensive patients with nephropathy due to type 2 dia

269 Some studies suggest that 10%-40% of elderly hypertensive patients with newly documented ESRD and no

270 We conclude that in hypertensive patients with nifedipine-induced GH, switch

271 e mortality or cardiovascular events because hypertensive patients with normal LVM seem to be a low-r

272 culating biomarkers of heart failure (HF) in hypertensive patients with normal resting echocardiograp

273 up A) and 4 control groups: obese, diabetic, hypertensive patients with normal vitamin D (group B; n=

274 e three annual time points (Year 1, 2 and 3) hypertensive patients with proteinuria had the worst gra

275 on of the WNK1 gene were found in a group of hypertensive patients with pseudohypoaldosteronism type

276 Hypertensive patients with relatively mild LVH without e

277 ive, double-blinded, randomized study of 291 hypertensive patients with symptomatic paroxysmal AF who

278 Data from 1590 hypertensive patients with type 2 diabetes in the Irbesa

279 btained macrophages from 76 obese, diabetic, hypertensive patients with vitamin D deficiency (25-hydr

280 tamin D (group B; n=15); obese, nondiabetic, hypertensive patients with vitamin D deficiency (group C

281 istance coronary vasomotor responsiveness in hypertensive patients without atherosclerosis.

282 In hypertensive patients without clinically evident vascula

283 to the risk of primary cardiac arrest among hypertensive patients without clinically recognized hear

284 s with disc hemorrhages compared with ocular hypertensive patients without disc hemorrhages.

285 grouped into normotensive patients (n = 98), hypertensive patients without left ventricular hypertrop

286 In 28 hypertensive patients without left ventricular hypertrop

287 h left ventricular hypertrophy (HTN LVH) and hypertensive patients without LVH (HTN non-LVH) using ca

288 Compared with hypertensive patients without LVH (n=191; 74.6%) and tho

289 By contrast, no hypertensive patients without LVH had an abnormally low

290 asurements between normotensive patients and hypertensive patients without LVH.

291 rtensive patients with LVH; group 2: n = 30, hypertensive patients without LVH; group 3: n = 68, norm